A biochimist works on a XAV-19 anti covid treatment (19)
lightboxes
You have to log in to have access to lightboxes
EN_01462003_1210
A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)
EN_01462003_1215
A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)
EN_01462003_1216
A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)
EN_01462003_1225
A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)
EN_01462003_1230
A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)
EN_01462003_1231
A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)
EN_01462003_1236
A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)
EN_01462003_1237
A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)
EN_01462003_1238
A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)
EN_01462003_1251
A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)
EN_01462003_1252
A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)
EN_01462003_1253
A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)
EN_01462003_1258
A biochimist carries samples as she works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, western France, on January 25, 2021. (Photo by LOIC VENANCE / AFP)
EN_01462003_1259
A biochimist prepares samples as she works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, western France, on January 25, 2021. (Photo by LOIC VENANCE / AFP)
EN_01462003_1260
A biochimist prepares samples as she works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, western France, on January 25, 2021. (Photo by LOIC VENANCE / AFP)
EN_01462003_1261
A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, western France, on January 25, 2021. (Photo by LOIC VENANCE / AFP)
EN_01462003_1262
A biochimist prepares samples as she works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, western France, on January 25, 2021. (Photo by LOIC VENANCE / AFP)
EN_01462003_1263
A biochimist prepares samples as she works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, western France, on January 25, 2021. (Photo by LOIC VENANCE / AFP)
EN_01462003_1278
A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, western France, on January 25, 2021. (Photo by LOIC VENANCE / AFP)
